Research Agenda for Antimicrobial Stewardship in the Veterans Health Administration

https://escholarship.org/uc/item/30n367b1

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 39(2)

0899-823X

Suda, KJ
Livorsi, DJ
Goto, M
et al.

2018-02-01

10.1017/ice.2017.299

Peer reviewed
Research agenda for antimicrobial stewardship in the Veterans Health Administration

Katie J. Suda, PharmD, M.S.; Daniel J. Livorsi, MD, MSc; Michihiko Goto, MD, MSc; Graeme Forrest, MD; Makoto M. Jones, MD; Melinda M. Neuhauser, PharmD, MPH; Brian M. Hoff B, PharmD; Dilek Ince, MD; Margaret Carrel, PhD; Rajeshwari Nair, PhD; Mary Jo Knobloch, PhD, MPH; Matthew Bidwell Goetz MB, MD.

1. Department of Veterans Affairs, Center of Innovation for Complex Chronic Healthcare, Edward Hines, Jr. VA Hospital, Hines, Illinois and Department of Pharmacy Systems, Outcomes, and Policy, University of Illinois at Chicago, Chicago, IL
2. Iowa City VA Health Care System, Iowa City, IA
3. Division of Infectious Diseases, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA
4. VA Portland Healthcare System, Portland, OR
5. VA Salt Lake City Health Care System and the University of Utah School of Medicine, Salt Lake City, UT
6. VA Pharmacy Benefits Management Services, Hines, IL
7. University of Iowa Hospital and Clinics, Iowa City, IA
8. Department of Geographical and Sustainability Sciences, College of Liberal Arts and Sciences, University of Iowa, Iowa City, IA
9. University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin and the William S. Middleton Memorial Veterans Hospital, Madison WI.
10. VA Greater Los Angeles Healthcare System and David Geffen School of Medicine at UCLA, Los Angeles, CA

*Joint first-authors

Running title: Research agenda for antimicrobial stewardship

Keywords: antimicrobial stewardship, research agenda, Veterans Health Administration

Word count: 2335

Corresponding author:
Daniel Livorsi, MD, MSc
Assistant Professor, Division of Infectious Diseases
University of Iowa Carver College of Medicine
Iowa VA Health Care System
601 Highway 6 West
Iowa City, IA 52246
Phone number: 319-338-0581 x 3871
Fax number: 319-887-4932
E-mail: daniel-livorsi@uiowa.edu
Abstract
Antimicrobial stewardship is vital to reducing the spread of antimicrobial resistance. A group of investigators and clinicians within the Veterans Health Administration set forth a research agenda for addressing antimicrobial resistance. This report describes research gaps in our knowledge of antimicrobial stewardship, including targets for inpatient and outpatient stewardship, metrics, and antimicrobial dosing and duration.
**Introduction**

Antimicrobial use is a key contributor to increasing antimicrobial resistance. Antimicrobial stewardship has been shown to decrease inappropriate antimicrobial use and, in turn, may reduce antimicrobial resistance and *Clostridium difficile* infection (CDI). Antimicrobial stewardship can also improve clinical outcomes for patients.

Veterans Health Administration (VHA) is a leader in promoting antimicrobial stewardship. Since 2011, the VHA National Antimicrobial Stewardship Taskforce (ASTF) has provided guidelines and resources for stewardship implementation at individual VHA facilities. In 2014, VHA mandated that every facility develop and maintain an antimicrobial stewardship program (ASP). The VHA ASP Directive tasked every VHA facility to have an ASP policy, conduct an annual evaluation of the ASP’s activities, and have a provider and a pharmacist champion. There were no requirements for facilities to adopt any specific set of ASP activities, allowing individual facilities to decide which elements to implement based on their own focus areas and available resources. This mandate was among the first in the United States, preceding similar directives from the Joint Commission and the Centers for Medicare and Medicaid Services. Recently, VHA investigators have partnered with the Centers for Disease Control and Prevention (CDC) to make use of novel antimicrobial usage metrics, including the Standardized Antimicrobial Administration Ratio (SAAR). They have also utilized the robust VA Corporate Data Warehouse (CDW) to determine the effectiveness of ASPs, evaluate outcomes and identify high-impact targets.

As the largest integrated healthcare system in the United States, VHA provides a unique opportunity to study strategies to improve antimicrobial-prescribing and the effectiveness of these interventions. Herein we describe the proceedings from a multidisciplinary conference focused on developing an agenda for antimicrobial stewardship research in inpatient and outpatient health care settings within VHA. The methods are described elsewhere (see preceding editorial). The research targets were designed specifically for health services
researchers within VHA, but our findings also have implications more broadly in private sector
health care settings.

**Recommendations**

**Inpatient Antimicrobial Stewardship**

**Optimal structure of ASP teams**

ASPs led by Infectious Disease (ID) specialists (physicians and/or pharmacists) have been successful at reducing unnecessary antimicrobial use and in improving appropriate use. However, due to staffing limitations, the implementation of stewardship across the continuum of healthcare is not feasible if an ID specialist must be the leader of every program. Many hospitals and non-acute residential care settings (e.g. long-term care) lack and/or cannot afford ID specialists to assist with stewardship. Even at hospitals that have ID specialists involved in stewardship, limitations in both resources and time prevent routine intervention on every antimicrobial prescribing decision. Future studies should identify barriers and facilitators to recruiting personnel outside the traditional stewardship team in the promotion of judicious antimicrobial-prescribing. Depending on the clinical setting, these stewardship extenders may include non-ID pharmacists, hospitalists, and other ancillary staff, such as nursing. In resource-limited settings, the use of telemedicine or information technology may provide opportunities for external facilitation. For example, local personnel at a resource-limited hospital could interact with an ID specialist who is based at a different location. ID physicians have provided HIV training to primary care and rural locations through the use of the VA Specialty Care Access Network-Extension for Community (SCAN-ECHO) program.

**Optimal Stewardship Activities**

Prospective audit-and-feedback and preauthorization are both effective strategies for antimicrobial stewardship within inpatient settings. Recent evidence suggests that prospective audit-and-feedback may be more effective than preauthorization in decreasing overall usage. Audit-and-feedback is based on a set of core principles, and the effectiveness of this strategy is dependent on how the feedback is delivered. Future studies should identify which methods for providing feedback are most effective for antimicrobial stewardship.
Using audit-and-feedback, ASPs can address multiple aspects of antimicrobial-prescribing, including empiric prescribing, antimicrobial dosing, de-escalation, duration of therapy, and intravenous-to-oral formulation conversion. It is unclear which of these targets has the greatest potential impact on key stewardship outcomes, such as preventing the emergence of antimicrobial resistance, reducing CDI, minimizing other adverse events and improving clinical outcomes. ASPs have limited resources and effort should be directed toward activities with the greatest potential impact.

As much as possible, stewardship processes should be incorporated into the daily workflow of frontline prescribers. Clinical decision support systems (CDSS) may be helpful in promoting thoughtful prescribing at the point-of-care, particularly by informing empiric prescribing decisions and prompting prescribers to de-escalate or discontinue therapy. Further research on CDSS should not only address the technical aspects of implementation but also the optimal methods for presenting complex data and antimicrobial recommendations in an understandable way.

Many ASPs have partnered with microbiology labs to leverage rapid diagnostics and biomarkers to improve antimicrobial-prescribing. Not only must these tests provide accurate and actionable results, but data must be standardized and results communicated effectively in order to change prescriber behavior. Developing better novel diagnostic tests and incorporating these tests into ASP efforts has great potential, because diagnostic uncertainty continues to be a major obstacle to appropriate antimicrobial use, especially in complex, dynamic environments such as critical care.

Evidence for Antimicrobial Dosing and Duration

Standard antimicrobial doses are inadequate to meet pharmacokinetic and pharmacodynamic (PK/PD) targets in many patients. There is limited data on what constitutes optimal dosing, especially for certain populations (e.g., obesity, critically ill) and categories of antimicrobials. Further research is needed.

Randomized-controlled trials have defined duration of antimicrobials for some infections, such as pneumonia and pyelonephritis, but for many infections, the recommended duration is
based on expert opinion (e.g., cystitis in men). If clinical trials and comparative effectiveness studies can provide robust data on the optimal duration of therapy for normative patients, it would facilitate stewardship efforts to ensure antimicrobials are administered for no longer than necessary. Studies on duration of therapy are also needed in immunocompromised and other patients with complex co-morbidities, who were often excluded from the above-mentioned trials.

**Stewardship Metrics**

We are at an early stage in understanding how best to evaluate stewardship processes and how these processes influence antimicrobial prescribing and clinical outcomes. In acute care hospitals, antimicrobial days per 1,000 days-present is currently the most commonly accepted metric for antimicrobial use. However, reasonable targets for reduction have yet to be established. These targets would need to account for differences in patient populations and also differences in types of antimicrobials prescribed (e.g. broad versus narrow-spectrum agents).

VHA has been working with the CDC to implement SAAR ratios as part of the Antimicrobial Use module within the National Healthcare Safety Network (NHSN). The SAAR is risk-adjusted for specific hospital characteristics, thereby representing an improvement over antimicrobial use metrics. However, the SAAR alone will not be sufficient in guiding more comprehensive evaluations at the facility level and identifying institution-specific opportunities for improvement. SAARs do not provide data as to why antimicrobials are being prescribed (i.e., use according to patient diagnosis) or how antimicrobials are being used (e.g., number of patients exposed, rates and timing of de-escalation or overall duration of therapy). Additional metrics should provide actionable data to clinicians and stewardship teams on their antimicrobial-prescribing behavior.

Making inter-facility comparisons through the use of metrics will have to account for inherent differences between hospitals. The SAAR attempts to adjust for some facility-level factors, such as facility bedsize, number of intensive care unit beds, and facility medical school affiliation. Adjustments may also have to be made for differences in case-mix, infection
prevention practices, and antimicrobial resistance rates. The best strategies to account for these key determinants of antimicrobial use have yet to be defined.

An overarching goal of stewardship is the reduction of antimicrobial resistance, therefore a major priority includes determining which metric(s) of antimicrobial use best predict patient- or population-level changes in antimicrobial resistance. Of course, the impact stewardship has on antimicrobial resistance will always be confounded by how successfully infection prevention practices prevent patient-to-patient transmission of resistant organisms.

Stewardship programs should also quantify clinical outcomes, including infection-related deaths and infection-related readmissions

**Outpatient Antimicrobial Stewardship**

**Optimal Antimicrobial Stewardship Personnel**

Guidelines for acute care ASPs recommend that leaders of stewardship strategies should be ID specialists. However, it is clear that few ID specialists are available in the outpatient sector. Therefore, it is of utmost importance to engage stewardship extenders in outpatient care settings (e.g., community pharmacists, public health departments). Patients are also an important component of outpatient stewardship, since patient demand is a known predictor for inappropriate antimicrobial prescribing. Data on methods by which to engage these stakeholders are limited. Research is also needed on identifying strategies to conduct external facilitation from the health system, payer, and/or federal level in the community.

**Optimal Stewardship Activities**

In the U.S., the majority of antimicrobial consumption is in the community and at least 30% of prescribing is inappropriate. Stewardship strategies have been evaluated in the community, but most studies have focused on clinic-delivered interventions among primary care physicians. A systematic review demonstrated that communication training and point-of-care testing are effective in reducing unnecessary antimicrobial use in clinics while education alone has failed to demonstrate a sustained benefit. Certain behavioral interventions have also reduced inappropriate antimicrobial use for acute respiratory tract infections. Continued evaluation of the impact of other stewardship strategies, such as the role of clinical decision
support systems, delayed-prescribing, and audit-and-feedback, should be conducted. A major priority is the identification of barriers and facilitators to implementing effective strategies across all outpatient settings and sustaining their effectiveness over time. Additionally, the generalizability of stewardship strategies across all outpatient care settings (e.g., emergency departments, urgent care, independent practices and across large health care networks) are unknown.

The majority of stewardship evaluations have focused on the outcome of unnecessary antimicrobial-prescribing among clinic-based primary care physicians. However, few evaluate appropriate antimicrobial selection (e.g., first-line agents) when antimicrobials are indicated (e.g., symptomatic bacteriuria). Evidence is also needed to support the impact of specific stewardship interventions in the community, especially for specialty physicians, non-physician providers, resource-limited settings and outpatient care delivered outside of the clinic setting (e.g., emergency departments, urgent care).

Outpatient Parenteral Antimicrobial Therapy (OPAT) is time-intensive and is frequently out of the purview of many outpatient stewardship initiatives. As a first step, we recommend studies of existing OPAT practices in VA.

**Stewardship Metrics**

Little evidence is available to identify optimal stewardship metrics for outpatient settings. While audits to assess overall use have been recommended, it is unclear if cases should be identified by ICD-10 codes (syndrome-based approach) or antimicrobial prescriptions (agent-based approach). The impact of outpatient stewardship on antimicrobial resistance, CDI and patient-centered outcomes have also not been definitively demonstrated, but research has suggested decreasing antimicrobial prescribing in outpatients has been associated with decreased resistance and CDI.

The use of metrics for peer-to-peer and interfacility comparisons will have to account for differences between patient panels, which could potentially include differences in co-morbidities and community resistance rates. Similar to the use of metrics for inpatient inter-facility
comparisons, the best strategies to account for these key determinants of antimicrobial use have yet to be defined.

**Implementation of Antimicrobial Stewardship Across Inpatient and Outpatient Settings**

Recent regulatory mandates both in VHA and outside of VHA should facilitate the expansion of inpatient stewardship efforts. While VA stewardship activities in outpatient care settings are increasing, these interventions remain limited.\(^4\)\(^0\) Data are not available on the prevalence of stewardship interventions in outpatient care settings in the private sector, but it is likely that these efforts also remain limited. Barriers and facilitators to broader implementation of outpatient stewardship have not been identified. In addition, optimal timing of outpatient stewardship interventions and the role of inpatient ASP teams to facilitate stewardship in outpatient healthcare settings remains unknown.

Achieving the research targets discussed above for both inpatients and outpatients should facilitate efforts of widespread stewardship implementation. For example, clarifying which stewardship activities are the most impactful should help to implement process in settings with limited resources and across large healthcare networks. Factors that ensure sustainability and scalability over time need to be identified.\(^4\)\(^1\)

**Conclusion:**

A multidisciplinary group of VHA experts identified several research targets for antimicrobial stewardship. Pursuit of research in these areas should improve healthcare for Veterans and the nation while continuing to address the crisis of antimicrobial resistance. Addressing these knowledge gaps in the VHA has the opportunity to be far-reaching, since health care systems in the private sector can apply what was learned in VHA to their own stewardship programs and initiatives. With a robust data source and a partnership between
clinical care and research, the VHA provides a unique opportunity to evaluate the implementation and impact of a national antimicrobial stewardship policy.

**Conflicts:** All authors report no conflicts of interest.

**Acknowledgments:** This work was supported in part by funding from the VA Health Services Research and Development (HSR&D) Service Center of Innovation (COIN) conference supplement for ("Setting the Clinical Research Agenda for MDROs in VA") [CIN 13-412] (all) and VA Quality Enhancement Research Initiative CARRIAGE Program [IP1 HX001993-01A1]. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. government. All authors report no conflicts of interest or financial disclosures relevant to this article.
### Table 1. Assessment of Current Evidence and Recommendations for Research Needs in Antimicrobial Stewardship

<table>
<thead>
<tr>
<th>Topic</th>
<th>Current Evidence</th>
<th>Research Needs (Specific QUERI six-step model addressed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inpatient antimicrobial stewardship</td>
<td>ID specialists are effective leaders of ASPs, but there are not enough ID specialists to provide on-site leadership across all healthcare facilities</td>
<td>Identify barriers and facilitators to recruiting personnel outside the traditional stewardship team (stewardship extenders) to promote judicious antimicrobial-prescribing (3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Develop strategies for external facilitation in resource-limited settings (4-5)</td>
</tr>
<tr>
<td>Optimal structure of ASP teams</td>
<td>Prospective audit-and-feedback and preauthorization are core stewardship strategies</td>
<td>Identify the highest impact targets for audit-and-feedback (2-3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Determine the optimal approach to providing feedback (3-5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Develop new diagnostics to facilitate more rapid feedback (1)</td>
</tr>
<tr>
<td>Optimal stewardship activities</td>
<td>Randomized-controlled trials have defined the duration of antimicrobials for some infections, such as pneumonia and pyelonephritis</td>
<td>Generate high-quality data to define the appropriate duration of antimicrobial therapy, including in patients who are immunocompromised or have complex co-morbidities (2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Determine what constitutes optimal antimicrobial dosing in obese patients and the critically ill (2)</td>
</tr>
<tr>
<td>Evidence for Antimicrobial Dosing and Duration</td>
<td></td>
<td>Develop and validate metrics to guide more comprehensive evaluations of antimicrobial-prescribing at the facility-level and to provide actionable data for effective, population-level stewardship interventions (2)</td>
</tr>
<tr>
<td></td>
<td>Days of therapy is the most commonly accepted metric for inpatient antimicrobial use</td>
<td>Methods for inter-facility risk-adjustment to enable benchmarking (2)</td>
</tr>
<tr>
<td>Outpatient antimicrobial stewardship</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>--------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td><strong>Optimal antimicrobial stewardship personnel</strong></td>
<td>Insufficient data to draw conclusions</td>
<td>Identify and implement strategies to engage stewardship extenders in the outpatient setting (4-5) Identify and implement strategies to conduct external facilitation from the level of the health system (5)</td>
</tr>
<tr>
<td><strong>Optimal stewardship activities</strong></td>
<td>Communication training, certain behavioral interventions, academic detailing and point-of-care testing can help reduce unnecessary antimicrobial use in clinics</td>
<td>Identify barriers and facilitators to implementing proven strategies and sustaining their effectiveness over time (3) Optimal components of academic detailing and use of other stewardship strategies in combination have not be determined, especially in non-academic settings in the absence of a research environment. (4) Determine whether strategies that work in primary care are also efficacious in other outpatient settings (2,3)</td>
</tr>
<tr>
<td><strong>Stewardship Metrics</strong></td>
<td>Insufficient data to draw conclusions</td>
<td>Develop and validate outpatient metrics (2) Develop strategies to compare antimicrobial-prescribing across providers/clinics while accounting for key determinants of antimicrobial use (2)</td>
</tr>
</tbody>
</table>

**ID** = infectious diseases

**ASP** = Antimicrobial stewardship

**SAAR** = Standardized Antimicrobial Administration Ratio
References


